Separately, Zacks Investment Research downgraded shares of ELEKTA from a buy rating to a hold rating in a report on Friday, October 27th.
ELEKTA (NASDAQ:EKTAY) traded up $0.27 on Monday, hitting $8.65. 18,079 shares of the stock traded hands, compared to its average volume of 3,710. ELEKTA has a 12-month low of $7.97 and a 12-month high of $11.18.
ELEKTA Company Profile
Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies.
Receive News & Ratings for ELEKTA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA and related companies with MarketBeat.com's FREE daily email newsletter.